Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) Short Interest Update

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT - Get Free Report) saw a large increase in short interest in October. As of October 15th, there was short interest totalling 4,610,000 shares, an increase of 5.3% from the September 30th total of 4,380,000 shares. Based on an average trading volume of 459,900 shares, the days-to-cover ratio is currently 10.0 days. Currently, 12.3% of the company's stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a "buy" rating and issued a $20.00 target price on shares of Checkpoint Therapeutics in a research report on Monday, September 16th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CKPT. XTX Topco Ltd acquired a new position in Checkpoint Therapeutics during the second quarter valued at approximately $34,000. Gladstone Institutional Advisory LLC boosted its holdings in Checkpoint Therapeutics by 141.4% during the third quarter. Gladstone Institutional Advisory LLC now owns 35,000 shares of the company's stock valued at $78,000 after acquiring an additional 20,500 shares during the period. Magnus Financial Group LLC grew its position in shares of Checkpoint Therapeutics by 12.9% in the third quarter. Magnus Financial Group LLC now owns 35,000 shares of the company's stock valued at $78,000 after purchasing an additional 4,000 shares during the last quarter. 180 Wealth Advisors LLC bought a new position in shares of Checkpoint Therapeutics in the second quarter worth about $96,000. Finally, Choreo LLC lifted its position in shares of Checkpoint Therapeutics by 200.9% during the 1st quarter. Choreo LLC now owns 57,922 shares of the company's stock worth $119,000 after purchasing an additional 38,672 shares during the last quarter. 22.00% of the stock is owned by institutional investors.

Checkpoint Therapeutics Stock Performance

Shares of NASDAQ CKPT traded down $0.18 during trading hours on Thursday, hitting $3.44. The stock had a trading volume of 1,648,736 shares, compared to its average volume of 509,357. The company has a market capitalization of $122.76 million, a P/E ratio of -1.28 and a beta of 1.30. The firm's 50-day moving average price is $2.53 and its two-hundred day moving average price is $2.18. Checkpoint Therapeutics has a 52 week low of $1.36 and a 52 week high of $3.97.

Checkpoint Therapeutics (NASDAQ:CKPT - Get Free Report) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.11. The business had revenue of $0.04 million during the quarter. As a group, analysts expect that Checkpoint Therapeutics will post -0.81 EPS for the current fiscal year.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.